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Abstract
Background: Irrreversible interstitial lung disease (ILD) is associated with high morbidity and mortality.
Palliative care needs of patients and caregivers are not routinely assessed; there is no tool to identify needs and
triage support in clinical practice.
Objective: The study objective was to adapt and face/content validate a palliative needs assessment tool for
people with ILD.
Methods: The Needs Assessment Tool: Progressive Disease-Cancer (NAT:PD-C) was adapted to reflect the
palliative care needs identified from the ILD literature and patient/caregiver interviews. Face and content
validity of the NAT:PD-ILD was tested using patient/caregiver focus groups and an expert consensus
group. Participants in the study were two English tertiary health care trusts’ outpatients clinics. There were four
focus groups: two patient (n= 7; n = 4); one caregiver (n= 3); and one clinician (n= 8). There was a single
caregiver interview, and an expert consensus group—academics (n= 3), clinicians (n= 9), patients (n= 4), and
caregivers (n = 2). Each item in the tool was revised as agreed by the groups. Expert consensus was reached.
Results: Overall, the tool reflected participants’ experience of ILD. Each domain was considered relevant.
Adaptations were needed to represent the burden of ILD: respiratory symptoms (especially cough) and concerns
about sexual activity were highlighted. All emphasized assessment of caregiver need as critical, and the role of
caregivers in clinical consultations.
Conclusions: The NAT:PD-ILD appears to have face and content validity. The inclusion of the family care-
giver in the consultation as someone with their own needs as well as a source of information was welcomed.
Reliability testing and construct validation of the tool are ongoing.
Introduction
Interstitial lung disease (ILD) represents a grouping ofirreversible ILDs. Idiopathic pulmonary fibrosis (IPF) is the
largest subgroup,with 5000 new cases annually inEngland and
Wales.1 IPF is a nonmalignant, progressive disease,2 with a
median survival of three years.3,4 Common symptoms include
breathlessness, cough, fatigue, and pain, often with psycho-
social, financial, and spiritual distress.5 Despite national
and international guidelines,6–9 assessments of palliative care
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needs are not part of routine clinical practice, and palliative
services are rarely accessed.6,10 The National Institute for
Health and Care Excellence (NICE) states that a needs as-
sessment tool should be used for people with IPF.7 Several are
available for people with cancer,11,12 but a clinician-rated tool
to identify ILD patients with palliative care needs and triage
referral to specialist palliative services does not currently exist.
The Australian Needs Assessment Tool:Progressive
Disease-Cancer (NAT:PD-C) is a clinician-administered
‘‘aide-memoire’’ designed to help clinicians identify patients
with palliative needs in daily practice and determine the
added value of palliative care service involvement in the care
of individual patients (for original questions, see Table 1,
column 1).13–15 It has face and content validity, acceptabil-
ity, and feasibility,13,14 and reduces unmet palliative care
needs.15 However, relevance to ILD and the United Kingdom
has not been assessed. The aim of this study was to adapt the
NAT:PD-C for use in people with ILD (NAT:PD-ILD) and to
test its face and content validity.
Methods
The NAT:PD-ILD adaptation was conducted in three steps
(October 2014 to April 2015). Ethical approval was obtained
prior to data collection from the National Research Ethics
Service North East – Tyne & Wear South (14/NE/0127).
Step 1. Preliminary adaptation
The NAT:PD-ILD was initially adapted from the
NAT:PD-C by incorporating supportive and palliative care
needs of patients with ILD and caregivers/relatives, identified
from the literature and secondary analysis of qualitative
patient/caregiver interviews.10,16–18
Step 2. Focus group review
The preliminary NAT:PD-ILD was reviewed by four focus
groups (twopatient groups; onecarer group; onecliniciangroup)
and a single caregiver interview held on hospital premises.
Participants
Eligible patient participants were consenting adults at-
tending ILD outpatients in two northern England sites. Cur-
rent caregivers were invited through the patient or directly.
Eligible clinicians were those caring for people with ILD in
one health care region.
Process
The NAT:PD-ILD was further adapted after the clinician
focus group. Following this, patient and caregiver focus
groups and a single caregiver interview (using the same
technique) were held. Participants were asked to discuss the
face validity of the tool and review the adapted NAT:PD-ILD
(including the instructions and prompts for clinicians) for
content: relevance, appropriateness, whether the items re-
flected their personal experience. They were asked to suggest
changes and/or to rectify omissions, which were incorporated
in the NAT:PD-ILD.
Step 3. Expert consensus group
An expert consensus group was identified by the research
team from their knowledge of their center teams and service
user groups. The same process as for the focus groups was
used. The final version of the NAT:PD-ILD was agreed on by
the research team.
Results
Participants
The clinician focus group (n= 8) included three consul-
tants (equivalent to attending physicians) and three specialist
respiratory trainee physicians (between five and eight years
postqualification), an ILD respiratory nurse specialist, and a
physiotherapist. Further details are withheld to protect ano-
nymity. Patients and caregiver characteristics are presented
(see Box 1). The expert consensus group consisted of aca-
demics (n = 4), physicians (n = 5), nurses (n = 3), patients
(n = 4), and caregivers (n = 2) from participating centers.
Summary changes
The changes made during the adaptation process from
initial NAT:PD-C to the preliminary NAT:PD-ILD and then
following focus group/interview and consensus group review
to the final version are shown in Tables 1 and 2, respectively.
Findings and changes from the clinician
focus group
All agreed that the tool reflected their own practice. Most
discussion focused on NAT:PD-ILD ‘‘red flags’’ identifying
patients at risk of significant concerns. Additions related to
ILD symptoms and support services were made. The care-
giver sections were clearly important; caregivers’ needs
might be overlooked, particularly if they were absent from
clinic. Clinicians were concerned about the balance of pro-
viding information and maintaining hope. The phrases sug-
gested in the NAT:PD-ILD to help the clinician to introduce
psychosocial-spiritual concerns were thought important to
facilitate its use.
Findings and changes from the patients
and caregivers focus groups/interview
Patients and caregivers considered that the NAT:PD-ILD
was a holistic assessment guide, would aid difficult discus-
sions, and would identify issues needing further attention
easily missed by ‘‘busy people.’’
Patients focused on physical symptoms (especially
cough—also bothersome for caregivers), the psychological
burdens of ILD, and their effect on daily activities. Patients
and caregivers described profound strain on relationships,
especially marital, with changes of roles/function, including
sexual issues. Patients described a loss of identity, feeling
consumed by their illness, and feeling dependent on care-
givers, which was isolating for both. Patients felt reluctant to
‘‘bother’’ clinicians by volunteering concerns and welcomed
a tool that prompted clinicians to assess and legitimize issues.
The patient/caregiver experience was of ‘‘thinking about
each other;’’ caregivers perceived that clinical consultations
were focused solely on patient needs and excluded their
contribution of important perspectives. They applauded the
explicit assessment of their concerns/needs. Caregivers felt
they took the psychological brunt of the patient’s distress and
frustrations, often felt lonely, and needed someone to talk to
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Table 1. NAT:PD-ILD Main Changes During Adaptation: Changes of the Content of Tool
(Item by Item) from Version 0.0 to Version 5.0
Centre for Health Research
and Psycho-oncology (2009)
NAT:PD-C version 0.0 NAT:PD-ILD version 1.0 NAT:PD-ILD version 5.0
Section 1: Priority referral for
further assessment
1. Does the patient have a
caregiver readily available if
required?
2. Has the patient or caregiver
requested a referral to an SPCS?
3. Do you require assistance in
managing the care of this patient
and/or family?
Section 1a: Red flags. If present, be
alert for unmet palliative care need
Red flag symptoms
X Clinical evidence of right heart
failure
X PO2 <6 kPa on air at rest and/or
respiratory failure with raised
CO2
X Has the patient or carer had
repeated unscheduled contact
with the ILD team?
X Failure to attend clinic today?
Section 1b: Priority referral for further
assessment
X No carer?
X Patient or carer request referral to
SPCS?
X You require assistance of SPCS?
Section 1a: Red flags. If present, be
alert for unmet palliative care need
Red flag symptoms
X Clinical evidence of right heart
failure
X Deteriorating performance
status
X Has the patient or carer had
repeated unscheduled contact
with hospitals?
X Failure to attend clinic today?
Section 1b: Priority referral for further
assessment
X No carer?
X Patient or carer request referral to
SPCS?
X You require assistance of SPCS?
Section 2: Patient well-being (Refer to
the back page for assistance)
1. Is the patient experiencing
unresolved physical symptoms
(including problems with pain,
sleeping, appetite, nausea, bowel,
breathing, or fatigue)?
2. Does the patient have problems
with daily living activities?
3. Does the patient have
psychological symptoms that are
interfering with well-being or
relationships?
4. Does the patient have concerns
about spiritual or existential
issues?
5. Does the patient have financial or
legal concerns that are causing
distress or require assistance?
6. From the health delivery point of
view, are there health beliefs,
cultural or social factors
involving the patient or family
that are making care more
complex?
7. Does the patient require
information about (tick any
options that are relevant): the
prognosis; the cancer; treatment
options; financial/legal issues;
medical/health/support services;
social/emotional issues
Section 2: Patient well-being (‘‘Does
the patient have.’’)
Who provided this information?
patient; caregiver; both
X Unresolved physical
symptoms (including SOB,
cough, leg edema, heartburn/
reflux/poor appetite, fatigue,
insomnia/
daytime drowsiness,
constipation, pain, cognition,
self-image or sex)?
X Unresolved psychological
symptoms?
X Problems with daily living
activities?
X Spiritual or existential
concerns?
X Financial or legal concerns?
X Health beliefs, cultural or social
factors making care
delivery complex?
X Information needs: prognosis;
diagnosis; treatment options;
financial/legal issues; support
services; social/emotional issues
Section 2: Patient well-being (‘‘Does
the patient have.’’)
Who provided this information?
patient; caregiver; both
X Unresolved physical
symptoms (including SOB/
cough/ mucous; leg edema,
heartburn/reflux/poor appetite,
fatigue/insomnia/daytime
drowsiness, constipation, pain,
cognition, voice, sore mouth,
mobility, self-image or sex)?
X Unresolved psychological
symptoms/loss of quality of life?
X Problems with daily living
activities?
X Spiritual or existential concerns
(issues about the meaning of life
and suffering)
X Work, financial, or legal
concerns?
X Health beliefs, cultural or social
factors making care
delivery complex?
X Information needs: prognosis;
diagnosis; treatment options;
financial/legal issues; support
services (social/emotional
issues)
Section 3: Ability of caregiver or
family to care for patient (Refer to
the back page for assistance)
Who provided this information?
(please tick one)
patient; caregiver; both
1. Is the caregiver or family
distressed about the patient’s
physical symptoms?
Section 3: Ability of carer or family to
care for patient
(‘‘Is the carer /family.’’)
Who provided this information?
(please tick one)
patient; caregiver; both
X Distressed about the patient’s
symptoms?
Section 3: Ability of carer or family to
care for patient
(‘‘Is the carer/family.’’)
Who provided this information?
(please tick one)
patient; caregiver; both
X Distressed about the patient’s
symptoms?
(continued)
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Table 1 (Continued)
Centre for Health Research
and Psycho-oncology (2009)
NAT:PD-C version 0.0 NAT:PD-ILD version 1.0 NAT:PD-ILD version 5.0
2. Is the caregiver or family having
difficulty providing
physical care?
3. Is the caregiver or family having
difficulty coping?
4. Does the caregiver or family have
financial or legal concerns that
are causing distress or
require assistance?
5. Is the family currently
experiencing problems that are
interfering with their functioning
or interpersonal relationships, or
is there a history of such
problems?
6. Does the caregiver or family
require information about (tick
any options that are relevant): the
prognosis; the cancer; treatment
options; financial/legal issues;
medical/health/support services;
social/emotional issues
X Having difficulty providing
physical care?
X Having difficulty coping?
X Concerned about financial or
legal issues?
X Experiencing problems that are
interfering with interpersonal
relationships or functioning, or is
there a history of such problems?
X Information needs: prognosis;
the diagnosis; treatment options;
financial/legal issues; support
services; social/emotional issues
X Having difficulty providing
physical care?
X Having difficulty coping with
the patient’s psychological
symptoms?
X Concerned about financial or
legal issues?
X Experiencing problems that
are interfering with
interpersonal relationships or
functioning, or is there a
history of such problems?
X Information needs: prognosis;
the diagnosis; treatment
options; financial/legal issues;
support services (social/
emotional issues)
Section 4: Caregiver well-being (Refer
to the back page for assistance)
Who provided this information?
(please tick one)
patient; caregiver; both
1. Is the caregiver or family
experiencing physical, practical,
spiritual, existential, or
psychological problems that are
interfering with their well-being
or functioning?
2. Is the caregiver or family
experiencing grief over the
impending or recent death of the
patient that is interfering with
their well-being or functioning?
Section 4: Carer/family well-being
(‘‘Carer or family
experiencing.’’)
X Problems that are interfering
with their well-being or
functioning?
X Grief over the impending death
of the patient?
Section 4: Carer/family well-being
(‘‘Carer or family experiencing.’’)
X Unresolved psychosocial
problems or feelings (loneliness,
depression, anxiety, frustration)
that are interfering with their
well-being or functioning?
X Grief over the future death of
the patient?
If referral required for further
assessment or care, please complete
this section
1. Referral to: (name)
2. Referral to: (specialty):
general practitioner; social
worker; psychologist; specialist
palliative care service; medical
oncologist; radiation oncologist;
hematologist; other
3. Priority of assessment needed:
urgent (within 24 hours);
semi-urgent (2–7 days);
non-urgent (next available)
4. Discussed the referral with the
client: yes; no
5. Client consented to the
referral: yes; no
6. Referral from: name: /
position: / signature:
If further assessment required, please
complete this section
X Referral to: (name)
X Specialty: ILD nurse
specialist; pastoral care;
psychology; OT; PT; social
services; specialist palliative
care; other
X Priority of assessment needed:
urgent (within 24 hours);
semi-urgent (2–7 days);
non-urgent (next available)
X Patient aware of referral: yes; no
X Patient agrees to referral: yes; no
X Referral from: name: /
position: / signature:
If further assessment required, please
complete this section
X Liaison with:
X Referral to: (name)
X Specialty: ILD nurse
specialist; spiritual care;
psychology; OT; PT; social
services; specialist palliative
care; local/specialist ILD clinic;
other
X Priority of assessment needed:
urgent (within 24 hours);
semi-urgent (2–7 days);
non-urgent (next available)
X Patient aware of referral: yes; no
X Copy to general practitioner:
yes; no
X Referral from: name: /
position: / signature:
ILD, interstitial lung disease; kPa, kiloPascals; NAT:PD-C, needs assessment tool: progressive disease-cancer; NAT:PD-ILD, needs
assessment tool: progressive disease-interstital lung disease; OT, occupational therapy; PT, physical therapy; SOB, shortness of breath;
SPCS, specialist palliative care service.
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for themselves. Caring consumed time and energy with
consequent work and financial implications.
Patients and caregivers confirmed the need for opportu-
nities to discuss the future and to address current major de-
ficiencies in information, written or otherwise, about ILD and
services available. They believed that palliative care was
reserved for people dying with cancer and welcomed triaging
access to specialist palliative care services. They expressed
fear about dying, death, symptoms, and lack of help.
Expert consensus group
This group made minor changes to the NAT:PD-ILD. The
final tool was agreed on by the study project management and
steering group members.
Table 2. Summary of NAT:PD-ILD Changes
4 sections (domains) and 1 referral
section
Section 1
3 items concerning: if patient needs
a carer; if patient or carer asks for
PCS; if the clinician asks for help
for this situation
Section 2 (about the patient)
7 items concerning: physical
symptoms (n = 7); daily activities;
psychological symptoms; spiritual
or existential issues; financial or
legal concerns; health beliefs,
cultural or social factors; type of
information needed
Section 3 (about carer & patient)
6 items concerning: family
distressed and symptoms;
physical care; coping; financial or
legal
concerns; interpersonal
relationships; type of information
needed
Section 4 (carer)
2 items concerning: caregiver
problems (physical, practical,
spiritual, existential, or
psychological) and well-being;
grief and well-being
Referral section
Specialties: general practitioner;
social worker; psychologist;
SPCS; medical oncologist;
radiation
oncologist; hematologist; other
4 sections (domains) and 1 referral
section
Section 1 (2 subsections were
created):
- 4 items concerning ‘‘red flags:’’
heart failure; PO2/CO2; ILD team
contact; attend clinic
- 3 items concerning ‘‘priority
referral’’ (same as V0.0)
Section 2 (about the patient)
- Option of who provided
information was added
- Same 7 items, however:
More physical symptoms (n = 14)
were added;
shorter sentences with the same
content;
term ‘‘support services’’ to state
‘‘medical/health/support’’
Section 3 (about carer & patient)
- Same 6 items, however:
Shorter sentences with the same
content;
term ‘‘the cancer’’ changed to
‘‘the diagnosis,’’ and
‘‘medical/health/support’’ to
‘‘support services’’
Section 4 (carer)
- Same 2 items, however:
Substantial changes in sentence
structure
Referral section
- New specialties were added: ILD
nurse specialist; pastoral care;
OT; PT
- Options as general practitioner;
medical oncologist; radiation
oncologist; hematologist were
taken
- ‘‘Social worker’’ and
‘‘psychologist’’ were changed
to ‘‘social services’’ and
‘‘psychology’’
4 sections (domains) and 1 referral
section
Section 1
- PO2/CO2 issues changed to
‘‘deteriorating performance
status’’
- ‘‘Unscheduled contact with
hospitals’’ instead of ‘‘ILD team
contact’’
Section 2 (about the patient)
- Same 7 items, however:
More physical symptoms (n = 18)
were added;
‘‘loss of quality of life’’ was
added/related to ‘‘unresolved
psychological symptoms’’;
Explanation about spiritual
dimension was added;
‘‘work’’ added as a concern;
‘‘support services (social/
emotional issues)’’ replace
‘‘support services; social/
emotional issues’’
—simplified
Section 3 (about carer & patient)
- Same 6 items, however:
‘‘Patient’s psychological
symptoms’’ was related to ‘‘
coping’’
‘‘support services (social/
emotional issues)’’ replace
‘‘support services; social/
emotional issues’’
Section 4 (carer)
- Same 2 items, however:
Substantial changes in sentence
structure
Referral section
- Local/specialist ILD clinic and
‘‘copy to general practitioner’’
were added
- ‘‘pastoral care’’ was changed to
‘‘spiritual care’’
The initial four sections from NAT:PD-C were kept in the final NAT:PD-ILD tool. Two subsections were added in section 1. In section 2,
specific ILD symptoms were added. In section 3, psychosocial variables were grouped. Section 4 had sentence structure changes. Other
specialties to refer to were added in the referral section.
ILD, interstitial lung disease; NAT:PD-ILD, needs assessment tool: progressive disease-interstital lung disease; PCS, palliative care
service; SPCS, specialist palliative care service.
Box 1. Demographics from Patient and Caregiver
Focus Group/Interviewa
Mean age [range] 70 [55–89] years
Male 4
Mean time from diagnosis [range] 40 [1–81] months
Home-oxygen 9
Have a caregiver 8
White British 11
Caregivers focus group (n= 3); interview (n = 1)
Mean age [range] 64 [64–65] years
Male 1
White British 4
aPatients N = 11 (FG1 = 7; FG2= 4).
FG, focus group.
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Discussion
The appearance and content of the adapted NAT:PD-ILD
reflected the experience of patients, caregivers, and clini-
cians. Changes from the cancer-specific version were re-
quired to deal with differences between diseases and between
service configuration.
The emphasis on respiratory symptoms by patients was not
surprising, but cough was especially disruptive to caregivers.
There was strong support for a caregiver assessment in the
context of patient concerns. Caregivers felt marginalized,
risking missed useful information about the patient and a lost
opportunity for support. This echoes previous studies19 and
contrasts with cancer services where there is public and
professional awareness of the wide-reaching effects of can-
cer.20 Coordinated, multiprofessional services support the
patient and family from prediagnosis through treatment to
survivorship and end-of-life care, with evidence-based inte-
grated palliative services available in many service models
from diagnosis21 alongside a plethora of printed and online
information and financial advice.22,23 In many countries,
specialist palliative care services are less or not at all ac-
cessible to patients with nonmalignant disease.24,25
The model of multiprofessional holistic care in IPF is re-
commended by NICE26 but is poorly implemented, espe-
cially with regard to psychosocial support, advance care
planning, and access to palliative care. Advanced commu-
nication skills training for cancer professionals was embed-
ded in the National Cancer Plan 2000 in the United
Kingdom27 but is unavailable to ILD clinicians, despite the
patient and caregiver distress associated with ILD.
In England and Wales, over 1.4 million people provide
50 hours or more unpaid care weekly.28 The impact of pro-
viding care with advancing disease and at the end of life for
family members has been highlighted,29 but effective inter-
ventions to support the caregivers are less well defined. The
NAT:PD-ILD could provide a valuable first step to identify
and address caregiver needs alongside those of the patients.
Implications for research
Reliability testing and construct validation are ongoing.
The cost effectiveness of the NAT:PD-ILD in reducing un-
met need should be tested in well-designed clinical trials,
including consideration of factors likely to affect im-
plementation in practice, e.g., consultation time, clinician
training needs, and resource implications. Consultation time
did not increase with use of the original tool.30
Implications for clinical practice
Clinician-administered tools may prompt discussion of
issues between patients, families, and health profession-
als;31,32 provide needs-driven management;33–35 help to pri-
oritize resources; and identify areas for improvement.32,35
Although further work is needed, there are immediate clinical
implications. First, caregivers should be encouraged to attend
and contribute to the consultation, which should include an
assessment of their needs. Second, ILD clinicians should
access advanced communication and basic palliative care
skills training. Last, there is an urgent need for education of
the public and professionals that palliative care should be
driven by individual needs and not restricted by diagnosis or
perceived short-term prognosis.
Strengths and limitations
The use ofmultiple approaches drawing on clinical services
from several areas in England is a strength. The focus groups
were small and not widely representative. However, the
findings are consistent with published literature and generated
a tool that was endorsed by expert consensus.
Conclusions
The adapted NAT:PD-ILD appears to have face/content
validity. Immediate implications for clinical practice include
the need for active assessment of caregiver needs and pallia-
tive care and communication skills training for ILDclinicians.
Reliability testing and construct validation are ongoing.
Further study to test the cost effectiveness and practical im-
plementation of the tool is required.
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